BioMarin Pharmaceutical (NASDAQ: [[ticker:BMRN]]), the Novato, CA-based maker of drugs for rare diseases, said it has agreed to acquire Milwaukee, WI-based ZyStor Therapeutics for $22 million upfront, plus another $93 million if certain milestones are met, bringing the total value of the deal to $115 million. ZyStor is developing enzyme replacement therapies for lysosomal storage disorders. Its lead drug candidate is for the treatment of Pompe disease.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman